LTS Acquires Renaissance Lakewood to Expand CDMO Capabilities in Nasal Drug Delivery
Key Insights
LTS LOHMANN Therapie-Systeme AG announced the acquisition of Renaissance Lakewood (search), a US-based CDMO specializing in nasal sprays and sterile dosage forms.
The acquisition adds approximately 500 employees and state-of-the-art manufacturing infrastructure for unit-dose, bi-dose, and multi-dose nasal sprays to LTS's global network.
Renaissance brings over 20 years of experience in nasal drug delivery and operates comprehensive R&D laboratories supporting formulation development and spray characterization.
LTS LOHMANN Therapie-Systeme AG, a leading pharmaceutical technology company, announced the acquisition of Renaissance Lakewood (search), LLC, a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. The strategic acquisition expands LTS's global manufacturing network and strengthens its position in the competitive CDMO market.
Strategic Expansion in Drug Delivery Technologies
The acquisition represents a significant milestone in LTS's strategy to broaden its capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure, and a talented workforce of approximately 500 employees to the combined organization. This integration enables LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community.
Founded in 1979 and currently owned by RoundTable Healthcare Partners (search), Renaissance is headquartered in Lakewood, New Jersey. The company operates multiple manufacturing suites for unit-dose, bi-dose, multi-dose nasal sprays, and small-volume parenteral fill-finish vials. Its laboratories support R&D formulation development and spray characterization, making Renaissance a comprehensive partner from development through commercial launch.
Enhanced Global Manufacturing Network
With the acquisition, Renaissance facilities will become part of LTS's worldwide operations network, joining existing facilities in Andernach, Germany, West Caldwell, NJ, US, St. Paul, MN, US and Netanya, Israel. The expanded network positions LTS to serve pharmaceutical and biotech partners across a wider spectrum of therapeutic modalities.
"We are delighted to welcome Renaissance Lakewood (search) to the LTS family," said Bas van Buijtenen, CEO of LTS. "This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions. Renaissance's expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to offer even greater value to our partners and patients worldwide."
Complementary Technology Platforms
LTS develops and manufactures innovative drug delivery systems including Transdermal Patches (TTS), Oral Thin Films (OTF), and wearable drug delivery devices (OBDS). The company's commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS maintains its leading position through continuous refinement of its core technologies and advancement of emerging drug delivery technologies, including Microneedle Array Patches (MAP) for transdermal delivery of small and large molecules, biological actives and vaccines.
Renaissance's specialization in nasal drug delivery systems adds a critical capability to LTS's technology portfolio. With over 20 years of experience in nasal sprays and sterile dosage forms, Renaissance has established a consistent track record of providing exceptional service and resources to clients from the development stage through commercial launch.
Transaction Timeline and Integration
Serge Maltais, President & CEO of Renaissance, expressed enthusiasm about the combination: "I am incredibly proud of what we have built at Renaissance thanks to the hard work and dedication of our employees. Now, as part of the LTS family, our combined strengths will position us even better to meet the complex needs of our clients and deliver greater value to the industry."
The transaction is expected to close before the end of November 2025, subject to regulatory approvals. The acquisition aligns with LTS's commitment to innovation and excellence in drug delivery, positioning the combined organization to better serve pharmaceutical and biotech partners across diverse therapeutic applications.